ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Finance

The value of priority review vouchers for drugmakers is falling

by Ryan Cross
August 3, 2018 | APPEARED IN VOLUME 96, ISSUE 32

 

The value of priority review vouchers, which drugmakers can use to expedite U.S. FDA review of their products, seems to be dwindling. Kyowa Hakko Kirin and Ultragenyx Pharmaceutical recently sold a priority review voucher for $80.6 million to an undisclosed buyer. That’s half the average value that nine previous vouchers sold for. FDA awards the vouchers to companies that develop a drug for a neglected disease. The partners got it for Crysvita, which FDA approved in April to treat a rare form of rickets.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment